2005
DOI: 10.1002/art.20914
|View full text |Cite
|
Sign up to set email alerts
|

18F‐fluorodeoxyglucose positron emission tomography in the diagnosis and followup of idiopathic retroperitoneal fibrosis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
31
0
3

Year Published

2007
2007
2018
2018

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 68 publications
(35 citation statements)
references
References 11 publications
1
31
0
3
Order By: Relevance
“…However, inflammatory cells also show high uptake of FDG, particularly when activated [8]. Hence, several studies have recently highlighted the potential role of FDG PET in the assessment of inflammatory disease [1][2][3][4][5][6]. c Whole-body FDG PET coronal MIP image shows no pathological FDG uptake IRF usually presents as a fibroinflammatory retroperitoneal mass.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…However, inflammatory cells also show high uptake of FDG, particularly when activated [8]. Hence, several studies have recently highlighted the potential role of FDG PET in the assessment of inflammatory disease [1][2][3][4][5][6]. c Whole-body FDG PET coronal MIP image shows no pathological FDG uptake IRF usually presents as a fibroinflammatory retroperitoneal mass.…”
Section: Discussionmentioning
confidence: 99%
“…Positron emission tomography (PET) with fluorine-18-labeled deoxyglucose (FDG) has recently been introduced for evaluation of inflammatory disease including retroperitoneal fibrosis [1][2][3][4][5][6].…”
Section: Introductionmentioning
confidence: 99%
“…Although fixation does not systematically shows morphological data visualized by CT scan and MRI, PET scan assesses the extension of RPF, the vascular and the perivascular lesions [20,21].…”
Section: Pet-scann (Figure 9) [19]mentioning
confidence: 99%
“…It could also help in the monitoring of the RPF [21]. In the study of Serezal [15], this technique was performed in 11 patients, at different stages of the evolution of the RPF.…”
Section: Pet-scann (Figure 9) [19]mentioning
confidence: 99%
“…[48] It detects other sites of inflammation and discloses infections or neoplastic lesions as the cause of or aligning with RF. [48,49] And also, FDG PET can help to detect the presence of the metabolic activity of the residual tissue and, therefore, point out if further treatment is needed, as residual retroperitoneal mass usually persists after medical therapy. [5] It is still controversial whether patients diagnosed with RF on the basis of CT/MRI require retroperitoneal biopsy.…”
Section: Case Twomentioning
confidence: 99%